10-Q: AVITA Medical Q3 Loss Narrows Amid Revenue Headwinds, Leadership Shift

AVITA Medical reported a 19% reduction in net loss for Q3 2025, despite a 13% revenue decline, driven by cost savings and new product launches, while facing ongoing debt covenant challenges and a CEO transition.

Summary

• Net loss for Q3 2025 decreased by 19% to $13.2 million, compared to $16.2 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, decreased by 26% to $37.0 million, compared to $50.3 million in the prior year.
• Total revenues for Q3 2025 decreased by 13% to $17.1 million, primarily due to Medicare Administrative Contractor (MAC) reimbursement headwinds.
• Total revenues for the nine months ended September 30, 2025, increased by 18% to $54.0 million, driven by deeper market penetration, new accounts, and new product launches.
• Operating expenses for Q3 2025 decreased by 24% to $23.0 million, reflecting cost savings initiatives including sales force reduction and R&D capitalization.
• Operating expenses for the nine months ended September 30, 2025, decreased by 11% to $76.6 million.
• Gross profit margin for Q3 2025 was 81.3%, down from 83.7% in Q3 2024, primarily due to product mix and higher inventory reserves.
• Cash and cash equivalents stood at $15.4 million, with marketable securities at $7.9 million, totaling $23.3 million as of September 30, 2025.
• The company completed a private placement on August 12, 2025, raising $14.8 million gross ($13.8 million net) through the issuance of 3,440,377 shares (equivalent to 17,201,886 CHESS Depositary Interests).
• Cary Vance was appointed Interim Chief Executive Officer and will continue as Chairman of the Board, effective October 16, 2025, following James Corbett's departure.
• The company received a New Technology Add-On Payment (NTAP) for the RECELL System, effective October 1, 2025, providing up to $4,875 in additional Medicare reimbursement per case for acute non-thermal full-thickness skin defects.
• RECELL GO received CE Mark approval on September 14, 2025, enabling commercialization in Europe and other CE Mark markets.
• The company launched Cohealyx commercially in the U.S. on April 1, 2025.

Sentiment

Score: 4

Explanation: While the company showed improved net loss and operating cash flow due to cost savings, the significant Q3 revenue decline, ongoing debt covenant breaches requiring waivers, and explicit 'going concern' doubt create substantial financial uncertainty. New product approvals and reimbursement wins are positive, but the immediate financial stability concerns outweigh these developments.

Positives

• Net loss significantly improved by 19% in Q3 2025 and 26% for the nine-month period, demonstrating effective cost control.
• Operating expenses decreased by 24% in Q3 2025 and 11% for the nine-month period, driven by cost savings initiatives, including sales force reduction and R&D capitalization.
• Nine-month revenues increased by 18% to $54.0 million, indicating deeper market penetration and successful new product launches.
• Successful private placement raised $14.8 million gross, providing additional working capital and strategic flexibility.
• RECELL GO received CE Mark approval, opening new commercialization opportunities in Europe and other markets.
• CMS approved a New Technology Add-On Payment (NTAP) for the RECELL System, providing up to $4,875 in additional Medicare reimbursement per case for specific wound treatments, which is expected to drive broader hospital adoption.
• Clinical data showed RECELL reduced hospital stays by 36% for deep-partial thickness burns compared to traditional grafting.
• U.S. commercial launch of Cohealyx on April 1, 2025, expands the company's wound care portfolio.
• Net cash used in operating activities improved significantly to $25.8 million for the nine-month period, compared to $40.9 million in the prior year.

Negatives

• The company incurred a net loss of $13.2 million in Q3 2025 and an accumulated deficit of $396.8 million as of September 30, 2025.
• Total revenues for Q3 2025 decreased by 13% to $17.1 million, primarily due to Medicare Administrative Contractor (MAC) reimbursement headwinds.
• Gross profit margin decreased to 81.3% in Q3 2025 (from 83.7% in Q3 2024) and to 82.4% for the nine-month period (from 85.1% in prior year), attributed to product mix and higher inventory reserves.
• Management has determined it is probable the company will not maintain compliance with the minimum cash balance covenant of its Credit Agreement within the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The long-term portion of the credit facility ($42.4 million) has been reclassified as a current liability due to the going concern doubt.
• The company has repeatedly failed to meet trailing 12-month net revenue covenants for its loan facility, requiring multiple waivers (Q1 2025, Q2 2025, Q3 2025, and Q4 2025 amended).
• Investment in the vitiligo initiative has been paused due to a challenging and uncertain reimbursement environment.
• Other expense, net increased significantly by $1.7 million in Q3 2025, primarily due to non-cash charges related to loan facility amendments and changes in fair value.

Risks

• Going Concern: Management has determined it is probable the company will not be able to maintain compliance with the minimum cash balance covenant of its Credit Agreement within the next twelve months, raising substantial doubt about its ability to continue as a going concern. This could lead to the Lender accelerating repayment of the outstanding debt.
• Debt Covenants: The company has repeatedly failed to meet trailing 12-month net revenue covenants, requiring multiple waivers and amendments to the Credit Agreement. Future non-compliance could trigger default and acceleration of debt.
• Liquidity and Funding: There is no assurance that additional funding (equity financing, debt, or other agreements) will be available when needed, either on favorable terms or at all, to support future operations and debt obligations.
• Reimbursement Environment: Changes in reimbursement rates and coverage policy by third-party payors, specifically Medicare Administrative Contractor (MAC) reimbursement headwinds, have negatively impacted demand for the RECELL System and could reduce demand for products if healthcare providers face lower margins or administrative burdens.
• Macroeconomic Environment: Factors such as supply chain shortages, increased healthcare costs, inflation, competitive labor market, tariffs, and geopolitical conditions (e.g., conflicts in Russia, Ukraine, Middle East) could adversely impact operating results.
• Competition: Increased competition in the wound care market.
• Intellectual Property: Failure to obtain, maintain, and enforce intellectual property rights.
• Regulatory Approvals: Failure to obtain and/or maintain regulatory approvals and comply with applicable regulations.
• Clinical Studies: Uncertainties regarding the conduct or outcome of pre-clinical or clinical (human) studies.
• Partnerships: Inability to find and maintain partnerships relating to collaborations, strategic arrangements, and licensing arrangements, or third parties failing to uphold contractual duties.
• Coverage and Reimbursement: Inability to obtain and maintain favorable coverage and reimbursement determinations from third-party payors.
• Manufacturing Capacity: Ability to continue to scale manufacturing operations to meet product demand.
• Personnel: Ability to attract and retain qualified personnel, including management.
• Cybersecurity/Geopolitical Events: Impact of a cybersecurity breach, terrorist attack, geopolitical instability, pandemic, epidemic, or natural disaster.
• Contingent Liabilities: Obligation to pay up to an additional $3.0 million for Regenity development/manufacturing capacity, contingent on positive clinical study results.

Future Outlook

The company aims to increase market penetration in U.S. burn and trauma centers, expand adoption of its RECELL portfolio and new products like Cohealyx and RECELL GO mini, and commercialize RECELL GO in Europe and other CE Mark markets. It plans to continue post-market studies for Cohealyx and PermeaDerm in 2025 to develop clinical data. The company's strategic objectives include driving commercial revenue growth, generating positive cash flow, and achieving operating profitability, while also seeking additional business development opportunities. Advocacy efforts are progressing to resolve Medicare reimbursement headwinds, which are expected to drive revenue recovery. However, the reimbursement environment for vitiligo remains challenging, leading to a pause in investment in that area. The company is actively evaluating strategies, including additional equity financing and debt, to obtain required funding and address going concern issues.

Management Comments

• We are executing a focused strategy targeting approximately 200 U.S. burn and trauma centers—including legacy burn centers—that represent the highest value and volume in the country’s acute wound care landscape.
• By concentrating on burn and trauma centers, we aim to maximize impact and drive adoption of our portfolio across the most critical segments of acute wound care.
• While we believe this issue [MAC reimbursement headwinds] contributed to a decline in demand for the RECELL System during the first half of the year, recent advocacy efforts are progressing towards a resolution which is expected to drive revenue recovery.
• The macroeconomic environment may have unexpected adverse effects on businesses and healthcare institutions globally that may negatively impact our consolidated operating results.
• There remains significant uncertainty in the current macroeconomic environment due to factors including supply chain shortages, increased cost of healthcare, changes to inflation rates, a competitive labor market, tariffs, and other related global economic conditions and geopolitical conditions.
• As a consequence, we continue to pause investment in vitiligo.
• Management has determined that, absent any mitigating action, it is probable the Company will not be able to maintain compliance of the minimum cash balance covenant pursuant with the terms of its Credit Agreement within the next twelve months following the date of issuance of the Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

Industry Context

The acute wound care market is experiencing shifts in reimbursement policies and macroeconomic pressures, including supply chain issues and increased healthcare costs. AVITA Medical is strategically positioning its RECELL portfolio, PermeaDerm, and newly launched Cohealyx to address these needs, particularly in burn and trauma centers. The approval of NTAP for RECELL and the CE Mark for RECELL GO indicate regulatory progress and potential for market expansion, while the company navigates a challenging reimbursement landscape for certain applications like vitiligo. The focus on high-value burn and trauma centers aligns with a strategy to maximize impact in critical segments of acute wound care amidst broader industry uncertainties.

Comparison to Industry Standards

• The company's gross margin for RECELL products only was 83.6% for Q3 2025 and 84.5% for the nine months ended September 30, 2025, which is stated to be expected to remain in this range for future quarters. This can be compared to gross margins of other medical device companies in the wound care or regenerative medicine space.
• Clinical data presented at the 2025 British Burn Association and European Burns Association Congress demonstrated a 36% reduction in hospital stays for adults with deep-partial thickness burns treated with RECELL compared to traditional grafting, indicating a significant clinical benefit and potential cost-effectiveness advantage over conventional treatments.
• The NTAP approval for the RECELL System, providing up to $4,875 in additional Medicare reimbursement per case, positions RECELL favorably against other new technologies in acute non-thermal full-thickness skin defect treatment, as it recognizes the device's FDA Breakthrough Device status and clinical value.
• The company's strategy to target approximately 200 U.S. burn and trauma centers, representing the highest value and volume, suggests a focused approach to market penetration, which can be benchmarked against market share and adoption rates of competitors in similar specialized medical device markets.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that it believes will have a material adverse effect on its business or financial condition.

Related Party Transactions

• Issuance of 400,000 shares of Common stock to OrbiMed Advisors, LLC (the Lender) on August 7, 2025, as a condition for the Fifth Amendment to the Credit Agreement.
• Issuance of 145,180 Penny Warrants to the Lender on February 13, 2025, as a condition for the Fourth Amendment to the Credit Agreement.
• Agreement to add $500,000 to the principal balance of the Loan Facility with the Lender on November 5, 2025, in consideration for the Sixth Amendment.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises (S-3 filing, private placement). Share price likely to be influenced by ongoing going concern issues and debt covenant compliance, despite positive product developments.
• Employees: Cost savings initiatives led to reductions in sales force headcount. Changes in management (CEO departure, interim CEO appointment) may affect morale and strategic direction.
• Customers: New product launches (Cohealyx, RECELL GO mini) and NTAP approval for RECELL System offer expanded treatment options and improved reimbursement, potentially increasing access and adoption.
• Lenders: The company's repeated non-compliance with debt covenants and the "going concern" doubt pose a risk to the lenders, although waivers have been granted and additional shares/principal added as consideration.
• Suppliers: Continued operations and product development (PermeaDerm, Cohealyx) suggest ongoing relationships, but financial instability could pose risks.

Next Steps

• Continue enrollment of post-market study of Cohealyx in 2025 to develop clinical data.
• Continue enrollment of post-market study of PermeaDerm in 2025 to develop clinical data.
• Commercialize RECELL GO in the European Union, the U.K., and Australia after obtaining CE mark.
• Drive commercial revenue growth, generate positive cash flow, and achieve operating profitability.
• Seek additional business development opportunities complementary to target markets.
• Actively evaluate strategies to obtain required additional funding, including equity financing, issuing debt, or other financing agreements.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on Consolidated Financial Statements.
• Potentially make an additional $3.0 million payment to Regenity by January 4, 2026, contingent on positive clinical study results.
• Cary Vance's continued service on the Board following the 2026 Annual Meeting of Stockholders is subject to nomination by the Board and approval by stockholders.

Key Dates

Recommendation

While AVITA Medical demonstrated significant improvements in net loss and operating cash flow due to effective cost management, the 13% revenue decline in Q3 2025, driven by reimbursement headwinds, is a concern. The explicit "going concern" doubt, coupled with repeated breaches of debt covenants requiring waivers, introduces substantial financial risk and uncertainty. New product approvals (RECELL GO CE Mark, Cohealyx launch) and the NTAP for RECELL are positive catalysts for future growth and market expansion. However, these positive developments are currently overshadowed by the immediate financial stability challenges and the need for further capital raises. An investor should hold to monitor the company's ability to secure additional funding, achieve debt covenant compliance, and demonstrate sustained revenue recovery from the reimbursement issues, as these factors will be critical in determining long-term viability and stock performance.

Keywords

AVITA Medical, RCEL, 10-Q, Quarterly Report, Wound Care, RECELL System, RECELL GO, PermeaDerm, Cohealyx, SEC Filing, Financial Results, Net Loss, Revenue, Operating Expenses, Debt Covenants, Going Concern, Capital Raise, CEO Change, Cary Vance, Medicare Reimbursement, NTAP, CE Mark, Medical Devices, Biotechnology, Healthcare